Literature DB >> 19222113

Therapeutic effect of puerarin on non-alcoholic rat fatty liver by improving leptin signal transduction through JAK2/STAT3 pathways.

Peiyong Zheng1, Guang Ji, Zansong Ma, Tao Liu, Lianjun Xin, Hongzhong Wu, Xin Liang, Jianwen Liu.   

Abstract

In order to investigate the mechanism of the therapeutic effect of puerarin on non-alcoholic fatty liver disease, a non-alcoholic fatty disease male rat model was induced by a high fat diet, all rats were randomly divided into a blank group, model group, simavastatin group and puerarin group. After 4 weeks of drug treatment, the liver was slided to investigate pathological morphology. Elisa was used to measure the total cholesterol (TC), triglyeride (TG) in liver, and leptin content in serum. RT-PCR and Western blotting were employed to detect liver leptin mRNA receptor expression and P-JAK2, P-STAT3 expression levels in the liver respectively. The results showed that puerarin significantly decreased the TG, TC content in liver of the non-alcoholic fatty disease rats, ameliorated steatosis in liver, lowered liver inflammatory reaction, decreased leptin level in serum, and enhanced the expression of leptin receptor mRNA and P-JAK2/P-STAT3 level. All the results demonstrated that puerarin can exhibit therapeutic effect on non-alcoholic fatty liver disease by improving leptin signal transduction through JAK2/STAT3 pathways.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19222113     DOI: 10.1142/S0192415X09006692

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  11 in total

Review 1.  Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease.

Authors:  Hui Dong; Fu-Er Lu; Li Zhao
Journal:  Chin J Integr Med       Date:  2012-02-05       Impact factor: 1.978

Review 2.  Novel insights into the mechanisms whereby isoflavones protect against fatty liver disease.

Authors:  Long-Xin Qiu; Tong Chen
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

Review 3.  Signal transductions and nonalcoholic fatty liver: a mini-review.

Authors:  Lu Zeng; Wai J Tang; Jin J Yin; Bei J Zhou
Journal:  Int J Clin Exp Med       Date:  2014-07-15

4.  Puerarin alleviates osteoporosis in the ovariectomy-induced mice by suppressing osteoclastogenesis via inhibition of TRAF6/ROS-dependent MAPK/NF-κB signaling pathways.

Authors:  Long Xiao; Mengdan Zhong; Yu Huang; Jie Zhu; Wenkai Tang; Danyong Li; Jiandong Shi; Aiqing Lu; Huilin Yang; Dechun Geng; Hong Li; Zhirong Wang
Journal:  Aging (Albany NY)       Date:  2020-11-07       Impact factor: 5.682

Review 5.  Protective effect of isoflavones and triterpenoid saponins from pueraria lobata on liver diseases: A review.

Authors:  Heng He; Shuwei Peng; Xu Song; Renyong Jia; Yuanfeng Zou; Lixia Li; Zhongqiong Yin
Journal:  Food Sci Nutr       Date:  2021-12-10       Impact factor: 2.863

6.  Puerarin ameliorates nonalcoholic fatty liver in rats by regulating hepatic lipid accumulation, oxidative stress, and inflammation.

Authors:  Jingxuan Zhou; Nanhai Zhang; Adil Aldhahrani; Mohamed Mohamed Soliman; Liebing Zhang; Feng Zhou
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

Review 7.  Neuroprotection for ischemic stroke: moving past shortcomings and identifying promising directions.

Authors:  Ryan C Turner; Brandon Lucke-Wold; Noelle Lucke-Wold; Alisa S Elliott; Aric F Logsdon; Charles L Rosen; Jason D Huber
Journal:  Int J Mol Sci       Date:  2013-01-17       Impact factor: 5.923

8.  Comparison between the efficacies of curcumin and puerarin in C57BL/6 mice with steatohepatitis induced by a methionine- and choline-deficient diet.

Authors:  Yunliang Wang; Jian Li; Li Zhuge; Dongmei Su; Meijuan Yang; Shiying Tao; Junxiang Li
Journal:  Exp Ther Med       Date:  2013-12-24       Impact factor: 2.447

9.  Intervening TNF-α via PPARγ with Gegenqinlian Decoction in Experimental Nonalcoholic Fatty Liver Disease.

Authors:  Yun-Liang Wang; Li-Juan Liu; Wei-Han Zhao; Jun-Xiang Li
Journal:  Evid Based Complement Alternat Med       Date:  2015-06-28       Impact factor: 2.629

10.  Gegen Qinlian Decoction Ameliorates Hepatic Insulin Resistance by Silent Information Regulator1 (SIRT1)-Dependent Deacetylation of Forkhead Box O1 (FOXO1).

Authors:  Miao Sui; Guofang Chen; Xiaodong Mao; Xiao Wei; Yu Chen; Chao Liu; Yaofu Fan
Journal:  Med Sci Monit       Date:  2019-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.